Homozygote x Hemizygote Homozgous females and hemizygous males are viable and fertile. Vamp7 KO Cell Biology Research <a href='https://brc.riken.jp/mus/pcr01926'>Genotyping protocol -PCR-</a> Developed by Akihiro Harada, Institute for Molecular and Cellular Regulation, Gunma University in 2005. Two lines were generated (RBRC01926 and RBRC04855). 条件を付加する。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。<br>研究成果の公表にあたって謝辞の表明を必要とする。<br>寄託者（開発者）の承諾を得る。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。当該マウスの解析について述べた最初の文献がprintとして出版されてから2年間以内に使用を開始する際は共同研究とする。 FLP/frt system B6;129S4-Vamp7<tm1Aha> B6;129S4-Vamp7<tm1Aha> In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The RECIPIENT of BIOLOGICAL RESOURCE must obtain a prior written consent on use of it from the DEPOSITOR/DEVELOPER. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. Within a period of TWO years after the first paper concerning the analysis of the BIOLOGICAL RESOURCE is published, the RECIPIENT agree to use this BIOLOGICAL RESOURCE as a collaboration with the DEPOSITOR. Encephalomyocarditis virus (EMCV) internal ribosomal entry site (ires), E. coli neo, phage P1 loxP sites, yeast FRT (flipase recombination target) sites, mouse VAMP7 genomic DNA Cre/loxP system Homozygote x HemizygoteHomozgous females and hemizygous males are viable and fertile. Akihiro HARADA RBRC01926 C (3-6 months) 原田　彰宏 繁殖効率は特に問題なし。 Vamp7 KO, B6;129-Vamp7<tm1> J1 [129S4/SvJae] Vamp7遺伝子のfloxedマウス (Neo型) 。Vamp7は細胞内のタンパク質輸送において輸送小胞と細胞膜の融合に関与するSNAREタンパク室の一つ。上皮細胞や神経細胞などの極性を持つ細胞内での小胞輸送に関与している。エクソン3と4を挟むようにloxPが挿入され、FRT-SA-Ex 5,6,7,8-IRES-Neo-polyA-FRTカセットがエクソン4と5の間に挿入されている。 true Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> C（3〜6か月） Vamp7 floxed mice (Neo type). Exons 3 and 4 of the Vamp7 gene were flanked by loxP sites, an FRT-SA-Ex 5,6,7,8-IRES-Neo-polyA-FRT cassette was inserted between exons 4 and 5. Vamp7 is a member of VAMP (vesicle-associated membrane protein) subfamily of SNARES proteins which primarily mediate fusion of cellular transport vesicles with a target membrane, and ubiquitously expressed and in localized to the late endsome, the lysosome, and the trans-Golgi network (TGN). 群馬大学生体調節研究所・原田彰宏先生（2005）。2ライン（変異ES株違い）あり（RBRC01926、RBRC04855）。